• Multi-Project Drug Collaboration seeks to Identify Novel Targets

News & Views

Multi-Project Drug Collaboration seeks to Identify Novel Targets

Jan 21 2020

Biopharmaceutical company Phoremost announced that it will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease relevant pathways nominated by Otsuka Pharmaceutical Co, a world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics. Discoveries will be further validated and characterised by Otsuka as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.

Based on proprietary protein interference, or ‘PROTEINi®’, the SITESEEKER platform can probe the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease. This enables the systematic discovery of functionally active peptides which are directly linked to useful therapeutic applications.

Dr Chris Torrance, CEO of PhoreMost, said: “This collaboration with Otsuka is further recognition of the power of the SITESEEKER approach to drive the identification of novel, druggable targets. We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.”


Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions

Events

ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia

Miconex

Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA

EMC2024

Aug 25 2024 Copenhagen, Denmark

View all events